Free Trial

HLS Therapeutics (TSE:HLS) Shares Down 0.6% - Here's What Happened

HLS Therapeutics logo with Medical background

Key Points

  • HLS Therapeutics shares fell by 0.6% on Friday, trading at C$5.00, while the trading volume decreased significantly by 87% compared to its average daily volume.
  • The company has a high debt-to-equity ratio of 86.50 and a market capitalization of C$111.24 million, alongside a PE ratio of -5.01.
  • HLS Therapeutics specializes in acquiring and commercializing branded pharmaceutical products, focusing primarily on treatments for the central nervous system and cardiovascular specialties.
  • Need Better Tools to Track HLS Therapeutics? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

HLS Therapeutics Inc. (TSE:HLS - Get Free Report) shares dropped 0.6% on Friday . The company traded as low as C$5.00 and last traded at C$5.00. Approximately 1,765 shares changed hands during mid-day trading, a decline of 87% from the average daily volume of 13,170 shares. The stock had previously closed at C$5.03.

HLS Therapeutics Stock Performance

The stock has a market capitalization of C$111.24 million, a P/E ratio of -5.01 and a beta of 1.07. The company has a current ratio of 1.56, a quick ratio of 1.01 and a debt-to-equity ratio of 86.50. The stock's fifty day moving average price is C$4.92 and its two-hundred day moving average price is C$4.52.

About HLS Therapeutics

(Get Free Report)

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.

See Also

Should You Invest $1,000 in HLS Therapeutics Right Now?

Before you consider HLS Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HLS Therapeutics wasn't on the list.

While HLS Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk
3 Overlooked AI Stocks That Chipmakers Can’t Live Without

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines